2 Stocks With Dividend Yields of 4% or More to Buy in November

Source The Motley Fool

Key Points

  • Dividend stocks are being forgotten by investors right now.

  • Pfizer has a diversified portfolio with nice growth potential.

  • PepsiCo is recovering from fears over weight loss drugs.

  • 10 stocks we like better than Pfizer ›

In a soaring market where investors are focused on capital spending, artificial intelligence (AI), and revenue growth, there is little focus on dividends. This could be an opportunity for contrarian investors to buy forgotten stocks.

Few stocks trade at dividend yields above 4% today, but they are still out there. One is Pfizer (NYSE:PFE). Another is PepsiCo (NASDAQ:PEP). Here is why both dividend stocks could be great buys for your portfolio this November, while everyone else is focused on AI.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Pfizer's oncology bet

Once a household name, Pfizer has seen its stock stagnate after the COVID-19 pandemic vaccine surge. It also failed to get in on the GLP-1 weight loss party, with global competitors seeing huge revenue growth associated with these weight loss drugs.

However, Pfizer still has a few tricks up its sleeve as a diversified drug giant. Revenue was $16.6 billion last quarter, and revenue this fiscal year is expected to be between $62 billion and $64 billion. The drugmaker

has sales coming from many sources, including its pneumonia vaccine, cardiovascular drugs, and COVID-19 vaccines.

Long-term, the company is betting on the growth of oncology/cancer treatments. Last quarter, revenue grew 37% year over year from businesses it has acquired, including 39% growth at Seagen, a company it acquired in recent years to grow its cancer business.

Right now, the market is valuing Pfizer as a low-growth stock, with its dividend yield now at 5.9%. However, it may be turning itself into a growth stock again if the oncology portfolio can keep producing growth like this. This should help the company maintain its dividend payout and likely grow it in the years ahead.

PepsiCo's growth revival

Speaking of weight loss drugs, there has been a narrative over the last few years that the proliferation of weight loss drugs would hurt packaged food businesses like PepsiCo, which sells its namesake brand alongside the likes of Gatorade, Lay's chips, and Tostitos.

So far, its volumes have been hit a bit, with beverage volumes in North America down 2% year over year last quarter. However, Pepsi can still grow through international expansion and steady price increases for its products, which can offset a slight headwind from weight loss drugs.

Last quarter, revenue grew 5.6%, with stable core operating margins. As with Pfizer, investors are being overly pessimistic about PepsiCo because of the weight-loss drug risk. The stock trades at a dividend yield of just above 4%, even though its revenue and earnings growth should drive solid dividend increases in the years ahead.

Unless you think people will all of a sudden stop drinking Pepsi and eating Lay's over the next decade, Pepsi looks like a great dividend stock you can add to your portfolio in November and never sell.

Buying winning dividend stocks

Finding winning dividend stocks is not about hypergrowth, but durability. PepsiCo is not going to grow aggressively like a hypergrowth AI company. It doesn't have to in order to deliver solid dividend income and grow its dividend payout over decades.

Same with Pfizer. It may have a blockbuster drug from time to time, but the fact that it has so many diversified bets and a massive research budget means it can steadily produce revenue while one drug is lagging (like the COVID-19 vaccines) and others grow. This is why it not only pursues internal development but also acquires promising growth drugs to add to its arsenal, making it more immune to treatment volatility.

If you use this strategy of focusing on durability over growth, you can find some great dividend stocks for your portfolio. Use a dividend reinvestment program (DRIP), and you can start compounding your wealth over the next few decades.

Should you buy stock in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Plunges 13% in a Week as Market Retreats to $60,000 LevelBitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
Author  TradingKey
8 hours ago
Bitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
placeholder
Silver Price Falls Below $50 to Hit Near One-Year Low: Why Is Silver Falling? As of the Asian session on Monday (November 16), silver prices (XAGUSD) extended their recent decline, falling for the third consecutive trading day and dropping nearly 3% intraday to tra
Author  TradingKey
10 hours ago
As of the Asian session on Monday (November 16), silver prices (XAGUSD) extended their recent decline, falling for the third consecutive trading day and dropping nearly 3% intraday to tra
placeholder
Silver Price Forecast: XAG/USD hits yearly lows below $47.50 amid hawkish Fed sentimentSilver price (XAG/USD) extends its losses for the third successive day, trading around $47.50 per troy ounce during Asian hours on Monday. Silver prices fell to a yearly low of $47.34, pressured by a strengthening US Dollar (USD) and elevated Treasury yields.
Author  FXStreet
13 hours ago
Silver price (XAG/USD) extends its losses for the third successive day, trading around $47.50 per troy ounce during Asian hours on Monday. Silver prices fell to a yearly low of $47.34, pressured by a strengthening US Dollar (USD) and elevated Treasury yields.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
15 hours ago
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
placeholder
Weekly Report: Gold's $4,000 reclaim and Brent's $100 break were right calls — the silver call was wrongLast week this report said gold's $4,000 reclaim was not the trend and that Brent's supply premium was over. Gold fell 4.7% to $3,884.69 and Brent fell 2.52% to $95.84, so both were right. The call that missed was silver: we read a gold-silver ratio of 78.7 as silver being cheap, and the ratio instead broke above 80 to 81.1 as silver fell 5.35%. This report grades the three calls, explains the miss, and sets this week's scorecard around 3,852 gold, 93.73 Brent and 6.00 copper.
Author  Irene Q.
15 hours ago
Last week this report said gold's $4,000 reclaim was not the trend and that Brent's supply premium was over. Gold fell 4.7% to $3,884.69 and Brent fell 2.52% to $95.84, so both were right. The call that missed was silver: we read a gold-silver ratio of 78.7 as silver being cheap, and the ratio instead broke above 80 to 81.1 as silver fell 5.35%. This report grades the three calls, explains the miss, and sets this week's scorecard around 3,852 gold, 93.73 Brent and 6.00 copper.
goTop
quote